article thumbnail

FDA Upgrades Recall on 160,000+ Bottles of Thyroid Medication

Drugs.com

Food and Drug Administration (FDA) has upgraded a recall of a commonly prescribed thyroid medication due to what it described as "subpotent" active ingredients. THURSDAY, July 24, 2025 — The U.S. The recall of more than 160,000 bottles of.

FDA
article thumbnail

FDA Approves Polypill Widaplik for Hypertension

Drugs.com

Food and Drug Administration has approved Widaplik (telmisartan, amlodipine, and indapamide) for the treatment of hypertension in adults.The combination pill is the first and only FDA-approved triple combination.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Limits COVID-19 Boosters to Seniors, Other High-Risk Groups

Drugs.com

Food and Drug Administration (FDA) has decided that only seniors and people at high risk should get the latest COVID-19 booster shots this fall.The new framework, announced Tuesday, says adults 65 and older, and p. WEDNESDAY May 21, 2025 The U.S.

FDA
article thumbnail

FDA to Review and Possibly Ban Fluoride Supplements for Kids

Drugs.com

Food and Drug Administration (FDA) plans to review and possibly remove prescription fluoride supplements for children from the market.The FDA announced Tuesday that it intends to conduct the review by Oct. WEDNESDAY, May 14, 2025 The U.S.

FDA
article thumbnail

FDA Approves First Cream for Treating Chronic Hand Eczema, Anzupgo

Drugs.com

Food and Drug Administration (FDA) has signed off on the first-ever cream specifically approved for treating chronic hand eczema (CHE). THURSDAY, July 24, 2025 — The U.S. CHE is common condition marked by redness, itching and cracking on the.

article thumbnail

FDA to speed reviews for drugs supporting ‘national interests’

BioPharma Drive: Drug Pricing

A new pilot program announced by FDA Commissioner Martin Makary would award vouchers that could cut drug reviews to one or two months — but only for products that meet a special criteria.

FDA
article thumbnail

After delay, Kalvista wins FDA OK for drug to treat rare swelling disorder

BioPharma Drive: Drug Pricing

The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an on-time approval.

FDA